Kenvue Key Executives
This section highlights Kenvue's key executives, including their titles and compensation details.
Find Contacts at Kenvue
(Showing 0 of )
Kenvue Earnings
This section highlights Kenvue's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-06 | $0.26 | $0.26 |
| Read Transcript | Q3 | 2024 | 2024-11-07 | $0.27 | $0.28 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $0.28 | $0.32 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $0.25 | $0.28 |
| Read Transcript | Q4 | 2023 | 2024-02-08 | $0.28 | $0.31 |
| Read Transcript | Q3 | 2023 | 2023-10-28 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-07-20 | $0.29 | $0.32 |
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
$23.31
Stock Price
$44.55B
Market Cap
22.00K
Employees
Skillman, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Kenvue, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 29, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $15.46B | $15.44B | $14.95B | $15.05B | $14.47B |
| Cost of Revenue | $6.50B | $6.80B | $6.67B | $6.63B | $6.62B |
| Gross Profit | $8.96B | $8.64B | $8.29B | $8.42B | $7.85B |
| Gross Profit Ratio | 57.97% | 56.00% | 55.42% | 55.90% | 54.25% |
| Research and Development Expenses | $- | $399.00M | $375.00M | $355.00M | $320.00M |
| General and Administrative Expenses | $- | $4.33B | $4.28B | $4.02B | $3.73B |
| Selling and Marketing Expenses | $- | $1.35B | $1.36B | $1.46B | $1.23B |
| Selling General and Administrative Expenses | $6.33B | $5.68B | $5.63B | $5.48B | $4.96B |
| Other Expenses | $789.00M | $50.00M | $4.00M | $25.00M | $3.00M |
| Operating Expenses | $7.12B | $6.13B | $5.62B | $5.41B | $4.86B |
| Cost and Expenses | $13.61B | $12.93B | $12.28B | $12.04B | $11.48B |
| Interest Income | $- | $108.00M | $- | $- | $- |
| Interest Expense | $378.00M | $358.00M | $- | $- | $- |
| Depreciation and Amortization | $- | $627.00M | $644.00M | $731.00M | $746.00M |
| EBITDA | $1.84B | $3.17B | $3.64B | $3.87B | $3.79B |
| EBITDA Ratio | 11.91% | 20.56% | 22.39% | 25.61% | 53.51% |
| Operating Income | $1.84B | $2.51B | $2.67B | $2.92B | $-979.00M |
| Operating Income Ratio | 11.91% | 16.27% | 17.89% | 19.40% | -6.77% |
| Total Other Income Expenses Net | $-426.00M | $-322.00M | $-38.00M | $5.00M | $-37.00M |
| Income Before Tax | $1.42B | $2.19B | $2.64B | $2.92B | $-1.02B |
| Income Before Tax Ratio | 9.16% | 14.18% | 17.64% | 19.43% | -7.02% |
| Income Tax Expense | $385.00M | $526.00M | $550.00M | $894.00M | $-137.00M |
| Net Income | $1.03B | $1.66B | $2.06B | $2.08B | $-879.00M |
| Net Income Ratio | 6.66% | 10.77% | 13.81% | 13.80% | -6.08% |
| EPS | $0.54 | $0.90 | $1.08 | $1.08 | $-0.47 |
| EPS Diluted | $0.54 | $0.87 | $1.08 | $1.08 | $-0.47 |
| Weighted Average Shares Outstanding | 1.92B | 1.85B | 1.91B | 1.89B | 1.89B |
| Weighted Average Shares Outstanding Diluted | 1.92B | 1.92B | 1.91B | 1.89B | 1.89B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | January 01, 2023 | October 02, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.66B | $3.90B | $4.00B | $3.89B | $3.67B | $3.92B | $4.01B | $3.85B | $3.77B | $3.79B | $3.80B | $3.59B | $3.73B |
| Cost of Revenue | $1.59B | $1.62B | $1.64B | $1.65B | $1.62B | $1.67B | $1.79B | $1.73B | $1.67B | $1.66B | $1.65B | $1.63B | $1.75B |
| Gross Profit | $2.07B | $2.28B | $2.36B | $2.24B | $2.04B | $2.25B | $2.23B | $2.12B | $2.10B | $2.12B | $2.15B | $1.96B | $1.98B |
| Gross Profit Ratio | 56.53% | 58.50% | 58.90% | 57.60% | 55.70% | 57.50% | 55.50% | 55.20% | 55.80% | 56.10% | 56.60% | 54.50% | 53.10% |
| Research and Development Expenses | $- | $- | $105.00M | $100.00M | $133.00M | $78.00M | $99.00M | $89.00M | $103.00M | $90.00M | $94.00M | $88.00M | $102.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $237.00M | $- | $- | $- | $29.00M | $- | $- | $- | $27.00M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $1.35B | $- | $- | $- | $1.36B | $- | $- | $- | $1.46B |
| Selling General and Administrative Expenses | $1.52B | $1.59B | $1.53B | $1.41B | $1.59B | $1.53B | $1.52B | $1.50B | $1.39B | $1.33B | $1.21B | $1.35B | $1.49B |
| Other Expenses | $62.00M | $38.00M | $3.00M | $-1.00M | $- | $-25.00M | $-10.00M | $-15.00M | $82.00M | $- | $10.00M | $-6.00M | $16.00M |
| Operating Expenses | $1.59B | $1.63B | $1.64B | $1.51B | $1.59B | $1.54B | $1.52B | $1.49B | $1.57B | $1.39B | $1.30B | $1.34B | $1.47B |
| Cost and Expenses | $3.18B | $3.25B | $3.28B | $3.16B | $3.21B | $3.21B | $3.31B | $3.22B | $3.24B | $3.05B | $2.95B | $2.98B | $3.22B |
| Interest Income | $53.00M | $- | $- | $- | $18.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $148.00M | $96.00M | $92.00M | $95.00M | $96.00M | $100.00M | $53.00M | $1.00M | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $150.00M | $182.00M | $141.00M | $149.00M | $174.00M | $153.00M | $148.00M | $152.00M | $166.00M | $152.00M | $161.00M | $165.00M | $182.00M |
| EBITDA | $644.00M | $855.00M | $856.00M | $811.00M | $765.00M | $995.00M | $828.00M | $783.00M | $898.00M | $957.00M | $978.00M | $805.00M | $722.00M |
| EBITDA Ratio | 17.59% | 21.93% | 21.43% | 22.73% | 17.21% | 17.50% | 17.25% | 20.51% | 23.84% | 25.26% | 26.50% | 21.53% | 18.83% |
| Operating Income | $483.00M | $654.00M | $716.00M | $736.00M | $457.00M | $710.00M | $702.00M | $640.00M | $531.00M | $805.00M | $845.00M | $611.00M | $506.00M |
| Operating Income Ratio | 13.19% | 16.77% | 17.90% | 18.90% | 12.47% | 18.14% | 17.50% | 16.61% | 14.10% | 21.25% | 22.26% | 17.02% | 13.55% |
| Total Other Income Expenses Net | $-137.00M | $-77.00M | $-89.00M | $-123.00M | $-103.00M | $-125.00M | $-63.00M | $-31.00M | $-19.00M | $-25.00M | $-70.00M | $1.00M | $11.00M |
| Income Before Tax | $346.00M | $577.00M | $65.00M | $427.00M | $357.00M | $585.00M | $639.00M | $609.00M | $512.00M | $738.00M | $775.00M | $612.00M | $517.00M |
| Income Before Tax Ratio | 9.45% | 14.80% | 1.62% | 10.97% | 9.74% | 14.94% | 15.93% | 15.81% | 13.59% | 19.48% | 20.42% | 17.05% | 13.85% |
| Income Tax Expense | $53.00M | $194.00M | $7.00M | $131.00M | $30.00M | $147.00M | $209.00M | $279.00M | $151.00M | $152.00M | $171.00M | $84.00M | $106.00M |
| Net Income | $293.00M | $383.00M | $58.00M | $296.00M | $327.00M | $438.00M | $430.00M | $330.00M | $361.00M | $586.00M | $604.00M | $528.00M | $411.00M |
| Net Income Ratio | 8.00% | 9.82% | 1.45% | 7.60% | 8.92% | 11.19% | 10.72% | 8.57% | 9.58% | 15.47% | 15.91% | 14.71% | 11.01% |
| EPS | $0.15 | $0.20 | $0.03 | $0.15 | $0.17 | $0.23 | $0.22 | $0.17 | $0.21 | $0.34 | $0.32 | $0.28 | $0.22 |
| EPS Diluted | $0.15 | $0.20 | $0.03 | $0.15 | $0.17 | $0.23 | $0.22 | $0.17 | $0.21 | $0.34 | $0.32 | $0.28 | $0.22 |
| Weighted Average Shares Outstanding | 1.92B | 1.92B | 1.92B | 1.92B | 1.92B | 1.91B | 1.91B | 1.89B | 1.72B | 1.72B | 1.91B | 1.89B | 1.89B |
| Weighted Average Shares Outstanding Diluted | 1.92B | 1.92B | 1.92B | 1.92B | 1.92B | 1.91B | 1.91B | 1.89B | 1.72B | 1.72B | 1.91B | 1.89B | 1.89B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 29, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.07B | $1.38B | $1.23B | $740.00M | $618.00M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.07B | $1.38B | $1.23B | $740.00M | $618.00M |
| Net Receivables | $2.66B | $2.07B | $2.12B | $2.07B | $1.86B |
| Inventory | $1.59B | $1.85B | $2.23B | $1.70B | $1.69B |
| Other Current Assets | $205.00M | $814.00M | $459.00M | $411.00M | $434.00M |
| Total Current Assets | $5.53B | $6.14B | $5.88B | $4.93B | $4.59B |
| Property Plant Equipment Net | $1.85B | $2.18B | $1.82B | $1.83B | $1.96B |
| Goodwill | $8.84B | $9.27B | $9.19B | $9.81B | $10.33B |
| Intangible Assets | $8.47B | $9.62B | $9.85B | $10.70B | $11.61B |
| Goodwill and Intangible Assets | $17.32B | $18.89B | $19.04B | $20.51B | $21.94B |
| Long Term Investments | $- | $71.00M | $66.00M | $74.00M | $122.00M |
| Tax Assets | $184.00M | $158.00M | $147.00M | $189.00M | $193.00M |
| Other Non-Current Assets | $726.00M | $413.00M | $368.00M | $401.00M | $374.00M |
| Total Non-Current Assets | $20.08B | $21.71B | $21.44B | $23.00B | $24.58B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $25.60B | $27.85B | $27.32B | $27.93B | $29.18B |
| Account Payables | $2.25B | $2.49B | $1.83B | $1.83B | $1.58B |
| Short Term Debt | $1.55B | $643.00M | $35.00M | $47.00M | $- |
| Tax Payables | $74.00M | $142.00M | $329.00M | $357.00M | $393.00M |
| Deferred Revenue | $- | $- | $- | $-129.00M | $-160.00M |
| Other Current Liabilities | $1.86B | $2.21B | $1.73B | $1.81B | $5.52B |
| Total Current Liabilities | $5.74B | $5.48B | $3.93B | $4.04B | $7.49B |
| Long Term Debt | $7.05B | $7.78B | $9.01B | $82.00M | $160.00M |
| Deferred Revenue Non-Current | $- | $- | $214.00M | $-82.00M | $-160.00M |
| Deferred Tax Liabilities Non-Current | $2.26B | $2.62B | $2.43B | $2.43B | $1.76B |
| Other Non-Current Liabilities | $878.00M | $754.00M | $-8.07B | $976.00M | $1.41B |
| Total Non-Current Liabilities | $10.19B | $11.16B | $3.37B | $3.49B | $3.33B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $15.93B | $16.64B | $7.29B | $7.53B | $10.82B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $19.00M | $19.00M | $19.00M | $24.87B | $21.93B |
| Retained Earnings | $-93.00M | $429.00M | $- | $- | $- |
| Accumulated Other Comprehensive Income Loss | $-6.15B | $-5.38B | $-5.45B | $-4.47B | $-3.57B |
| Other Total Stockholders Equity | $15.89B | $16.14B | $-25.43B | $- | $- |
| Total Stockholders Equity | $9.67B | $11.21B | $20.02B | $20.40B | $18.36B |
| Total Equity | $9.67B | $11.21B | $20.02B | $20.40B | $18.36B |
| Total Liabilities and Stockholders Equity | $25.60B | $27.85B | $27.32B | $27.93B | $29.18B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $25.60B | $27.85B | $27.32B | $27.93B | $29.18B |
| Total Investments | $- | $71.00M | $66.00M | $74.00M | $122.00M |
| Total Debt | $8.61B | $8.43B | $116.00M | $258.00M | $320.00M |
| Net Debt | $7.54B | $7.04B | $-1.11B | $-482.00M | $-298.00M |
Balance Sheet Charts
| Breakdown | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | January 01, 2023 | October 02, 2022 | April 03, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.07B | $1.06B | $1.01B | $1.16B | $1.38B | $1.06B | $1.23B | $1.69B | $1.23B | $797.00M | $-740.00M | $740.00M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.48B | $- |
| Cash and Short Term Investments | $1.07B | $1.06B | $1.01B | $1.16B | $1.38B | $1.06B | $1.23B | $1.69B | $1.23B | $797.00M | $740.00M | $740.00M |
| Net Receivables | $2.66B | $2.85B | $2.24B | $2.16B | $2.07B | $2.11B | $2.10B | $2.11B | $2.12B | $2.14B | $- | $2.07B |
| Inventory | $1.59B | $1.82B | $1.85B | $1.88B | $1.85B | $1.89B | $2.03B | $2.22B | $2.23B | $2.13B | $- | $1.70B |
| Other Current Assets | $205.00M | $210.00M | $1.31B | $1.52B | $1.38B | $1.42B | $1.49B | $628.00M | $298.00M | $392.00M | $- | $411.00M |
| Total Current Assets | $5.53B | $5.94B | $5.88B | $6.10B | $6.14B | $5.89B | $6.22B | $6.44B | $5.88B | $5.46B | $740.00M | $4.93B |
| Property Plant Equipment Net | $1.85B | $1.78B | $2.13B | $2.00B | $2.18B | $1.87B | $1.83B | $1.84B | $1.93B | $1.70B | $- | $1.83B |
| Goodwill | $8.84B | $9.30B | $8.97B | $9.03B | $9.27B | $8.97B | $9.08B | $9.23B | $9.19B | $8.77B | $- | $9.81B |
| Intangible Assets | $8.47B | $8.89B | $8.76B | $9.38B | $9.62B | $9.49B | $9.68B | $9.84B | $9.85B | $9.54B | $- | $10.70B |
| Goodwill and Intangible Assets | $17.32B | $18.18B | $17.73B | $18.41B | $18.89B | $18.46B | $18.76B | $19.07B | $19.04B | $18.32B | $- | $20.51B |
| Long Term Investments | $- | $- | $41.00M | $41.00M | $71.00M | $76.00M | $78.00M | $7.75B | $66.00M | $- | $- | $74.00M |
| Tax Assets | $184.00M | $228.00M | $206.00M | $171.00M | $158.00M | $156.00M | $143.00M | $168.00M | $- | $- | $- | $189.00M |
| Other Non-Current Assets | $726.00M | $796.00M | $453.00M | $559.00M | $413.00M | $618.00M | $511.00M | $330.00M | $405.00M | $544.00M | $-740.00M | $401.00M |
| Total Non-Current Assets | $20.08B | $20.98B | $20.56B | $21.19B | $21.71B | $21.18B | $21.32B | $29.16B | $21.44B | $20.56B | $-740.00M | $23.00B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $25.60B | $26.93B | $26.44B | $27.28B | $27.85B | $27.08B | $27.54B | $35.59B | $27.32B | $26.02B | $- | $27.93B |
| Account Payables | $2.25B | $2.27B | $2.44B | $2.60B | $2.49B | $2.28B | $2.35B | $1.78B | $1.83B | $1.75B | $- | $1.83B |
| Short Term Debt | $1.59B | $1.69B | $1.47B | $1.57B | $643.00M | $559.00M | $799.00M | $32.00M | $35.00M | $- | $- | $47.00M |
| Tax Payables | $156.00M | $163.00M | $96.00M | $164.00M | $142.00M | $383.00M | $239.00M | $604.00M | $- | $- | $- | $357.00M |
| Deferred Revenue | $- | $- | $96.00M | $164.00M | $142.00M | $- | $- | $- | $- | $- | $- | $-129.00M |
| Other Current Liabilities | $1.74B | $1.82B | $1.94B | $1.83B | $2.21B | $1.94B | $1.91B | $1.79B | $2.06B | $2.12B | $- | $1.81B |
| Total Current Liabilities | $5.74B | $5.95B | $5.94B | $6.17B | $5.48B | $5.16B | $5.30B | $4.21B | $3.93B | $3.87B | $- | $4.04B |
| Long Term Debt | $7.13B | $7.14B | $7.14B | $7.13B | $7.78B | $7.79B | $7.80B | $7.76B | $81.00M | $- | $- | $82.00M |
| Deferred Revenue Non-Current | $- | $- | $88.00M | $98.00M | $97.00M | $- | $- | $- | $- | $- | $- | $-82.00M |
| Deferred Tax Liabilities Non-Current | $2.26B | $- | $2.39B | $2.57B | $2.62B | $2.52B | $2.68B | $2.68B | $- | $- | $- | $2.43B |
| Other Non-Current Liabilities | $802.00M | $3.20B | $797.00M | $797.00M | $754.00M | $717.00M | $717.00M | $659.00M | $3.34B | $3.23B | $- | $976.00M |
| Total Non-Current Liabilities | $10.19B | $10.34B | $10.33B | $10.50B | $11.16B | $11.02B | $11.20B | $11.10B | $3.42B | $3.23B | $- | $3.49B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $15.93B | $16.28B | $16.27B | $16.66B | $16.64B | $16.18B | $16.50B | $15.31B | $7.35B | $7.09B | $- | $7.53B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $19.00M | $19.00M | $19.00M | $19.00M | $19.00M | $19.00M | $19.00M | $25.52B | $25.43B | $25.15B | $- | $24.87B |
| Retained Earnings | $-93.00M | $7.00M | $17.00M | $342.00M | $429.00M | $485.00M | $430.00M | $- | $- | $- | $- | $- |
| Accumulated Other Comprehensive Income Loss | $-6.15B | $-5.36B | $-5.83B | $-5.67B | $-5.38B | $-5.74B | $-5.51B | $-5.24B | $-5.46B | $-6.23B | $20.40B | $-4.47B |
| Other Total Stockholders Equity | $15.89B | $15.98B | $15.98B | $15.94B | $16.14B | $16.13B | $16.10B | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $9.67B | $10.64B | $10.18B | $10.62B | $11.21B | $10.89B | $11.04B | $20.28B | $19.97B | $18.93B | $20.40B | $20.40B |
| Total Equity | $9.67B | $10.64B | $10.18B | $10.62B | $11.21B | $10.89B | $11.04B | $20.28B | $19.97B | $18.93B | $20.40B | $20.40B |
| Total Liabilities and Stockholders Equity | $25.60B | $26.93B | $26.44B | $27.28B | $27.85B | $27.08B | $27.54B | $35.59B | $27.32B | $26.02B | $20.40B | $27.93B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $25.60B | $26.93B | $26.44B | $27.28B | $27.85B | $27.08B | $27.54B | $35.59B | $27.32B | $26.02B | $20.40B | $27.93B |
| Total Investments | $- | $- | $41.00M | $41.00M | $71.00M | $76.00M | $78.00M | $7.75B | $66.00M | $- | $1.48B | $74.00M |
| Total Debt | $8.72B | $8.83B | $8.61B | $8.70B | $8.43B | $8.35B | $8.60B | $7.79B | $116.00M | $80.00M | $- | $258.00M |
| Net Debt | $7.65B | $7.77B | $7.59B | $7.54B | $7.04B | $7.29B | $7.37B | $6.10B | $-1.11B | $-717.00M | $740.00M | $-482.00M |
Annual Cash Flow
| Breakdown | December 29, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $1.03B | $1.66B | $2.09B | $2.03B | $-879.00M |
| Depreciation and Amortization | $622.00M | $627.00M | $644.00M | $731.00M | $746.00M |
| Deferred Income Tax | $-285.00M | $-114.00M | $157.00M | $568.00M | $-801.00M |
| Stock Based Compensation | $254.00M | $188.00M | $137.00M | $141.00M | $115.00M |
| Change in Working Capital | $- | $797.00M | $-513.00M | $-3.13B | $4.24B |
| Accounts Receivables | $-218.00M | $44.00M | $-142.00M | $-303.00M | $265.00M |
| Inventory | $182.00M | $349.00M | $-582.00M | $-77.00M | $109.00M |
| Accounts Payables | $-536.00M | $390.00M | $52.00M | $330.00M | $154.00M |
| Other Working Capital | $- | $14.00M | $159.00M | $-3.08B | $3.71B |
| Other Non Cash Items | $148.00M | $6.00M | $13.00M | $-5.00M | $-26.00M |
| Net Cash Provided by Operating Activities | $1.77B | $3.17B | $2.52B | $334.00M | $3.40B |
| Investments in Property Plant and Equipment | $-434.00M | $-469.00M | $-375.00M | $-295.00M | $-229.00M |
| Acquisitions Net | $- | $21.00M | $-10.00M | $136.00M | $176.00M |
| Purchases of Investments | $- | $- | $-5.00M | $-12.00M | $-30.00M |
| Sales Maturities of Investments | $- | $- | $8.00M | $77.00M | $-146.00M |
| Other Investing Activities | $9.00M | $-40.00M | $-8.00M | $-77.00M | $146.00M |
| Net Cash Used for Investing Activities | $-425.00M | $-488.00M | $-390.00M | $-171.00M | $-83.00M |
| Debt Repayment | $159.00M | $8.25B | $14.00M | $-7.00M | $-11.00M |
| Common Stock Issued | $- | $4.24B | $- | $- | $- |
| Common Stock Repurchased | $-235.00M | $- | $- | $- | $- |
| Dividends Paid | $-1.55B | $-14.55B | $- | $- | $- |
| Other Financing Activities | $63.00M | $-460.00M | $-1.60B | $7.00M | $-3.45B |
| Net Cash Used Provided by Financing Activities | $-1.56B | $-2.53B | $-1.58B | $- | $-3.46B |
| Effect of Forex Changes on Cash | $-91.00M | $-2.00M | $-61.00M | $-41.00M | $9.00M |
| Net Change in Cash | $-312.00M | $151.00M | $491.00M | $122.00M | $-134.00M |
| Cash at End of Period | $1.07B | $1.38B | $1.23B | $740.00M | $618.00M |
| Cash at Beginning of Period | $1.38B | $1.23B | $740.00M | $618.00M | $752.00M |
| Operating Cash Flow | $1.77B | $3.17B | $2.52B | $334.00M | $3.40B |
| Capital Expenditure | $-434.00M | $-469.00M | $-375.00M | $-295.00M | $-229.00M |
| Free Cash Flow | $1.33B | $2.70B | $2.15B | $39.00M | $3.17B |
Cash Flow Charts
| Breakdown | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | January 01, 2023 | October 02, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $293.00M | $383.00M | $58.00M | $296.00M | $327.00M | $577.00M | $430.00M | $330.00M | $361.00M | $586.00M | $604.00M | $528.00M | $411.00M |
| Depreciation and Amortization | $150.00M | $182.00M | $141.00M | $149.00M | $174.00M | $153.00M | $148.00M | $152.00M | $166.00M | $152.00M | $161.00M | $165.00M | $182.00M |
| Deferred Income Tax | $-40.00M | $-40.00M | $-201.00M | $-4.00M | $14.00M | $-283.00M | $-12.00M | $167.00M | $- | $- | $42.00M | $20.00M | $71.00M |
| Stock Based Compensation | $54.00M | $58.00M | $61.00M | $81.00M | $113.00M | $2.00M | $38.00M | $35.00M | $31.00M | $30.00M | $41.00M | $35.00M | $35.00M |
| Change in Working Capital | $262.00M | $482.00M | $-143.00M | $-339.00M | $305.00M | $248.00M | $126.00M | $118.00M | $1.00M | $-89.00M | $-43.00M | $-408.00M | $300.00M |
| Accounts Receivables | $125.00M | $-110.00M | $-109.00M | $-124.00M | $141.00M | $-42.00M | $-78.00M | $23.00M | $68.00M | $-66.00M | $-84.00M | $-60.00M | $92.00M |
| Inventory | $169.00M | $62.00M | $14.00M | $-63.00M | $74.00M | $132.00M | $126.00M | $17.00M | $-47.00M | $-169.00M | $-172.00M | $-194.00M | $27.00M |
| Accounts Payables | $37.00M | $-336.00M | $-56.00M | $-181.00M | $159.00M | $-98.00M | $383.00M | $-54.00M | $- | $- | $84.00M | $-126.00M | $328.00M |
| Other Working Capital | $-69.00M | $866.00M | $8.00M | $29.00M | $262.00M | $256.00M | $-305.00M | $132.00M | $-20.00M | $146.00M | $129.00M | $-28.00M | $-147.00M |
| Other Non Cash Items | $74.00M | $-816.00M | $524.00M | $851.00M | $104.00M | $-23.00M | $12.00M | $353.00M | $85.00M | $57.00M | $537.00M | $-2.00M | $20.00M |
| Net Cash Provided by Operating Activities | $793.00M | $249.00M | $440.00M | $287.00M | $950.00M | $674.00M | $742.00M | $802.00M | $644.00M | $736.00M | $807.00M | $338.00M | $1.01B |
| Investments in Property Plant and Equipment | $-132.00M | $-59.00M | $-90.00M | $-153.00M | $-223.00M | $-114.00M | $-77.00M | $-55.00M | $-159.00M | $-103.00M | $-76.00M | $-37.00M | $-123.00M |
| Acquisitions Net | $- | $- | $- | $- | $7.00M | $- | $- | $14.00M | $- | $- | $2.00M | $- | $90.00M |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $3.00M | $5.00M | $1.00M | $-49.00M | $9.00M | $- | $14.00M | $-8.00M | $-5.00M | $1.00M | $-5.00M | $90.00M |
| Net Cash Used for Investing Activities | $-132.00M | $-56.00M | $-85.00M | $-152.00M | $-265.00M | $-105.00M | $-77.00M | $-41.00M | $-167.00M | $-108.00M | $-73.00M | $-42.00M | $-33.00M |
| Debt Repayment | $-108.00M | $209.00M | $-102.00M | $160.00M | $77.00M | $-245.00M | $740.00M | $7.67B | $- | $15.00M | $1.00M | $6.00M | $-2.00M |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $4.24B | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-121.00M | $-23.00M | $- | $-91.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $-393.00M | $-393.00M | $-383.00M | $-383.00M | $-383.00M | $-383.00M | $-13.79B | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $35.00M | $45.00M | $-5.00M | $-12.00M | $-77.00M | $-98.00M | $1.00M | $-286.00M | $-63.00M | $-650.00M | $-676.00M | $-216.00M | $-898.00M |
| Net Cash Used Provided by Financing Activities | $-587.00M | $-162.00M | $-490.00M | $-326.00M | $-383.00M | $-726.00M | $-8.81B | $7.39B | $-63.00M | $-635.00M | $-675.00M | $-210.00M | $-900.00M |
| Effect of Forex Changes on Cash | $-61.00M | $12.00M | $-6.00M | $-36.00M | $18.00M | $-12.00M | $-14.00M | $6.00M | $20.00M | $-34.00M | $-50.00M | $3.00M | $-15.00M |
| Net Change in Cash | $13.00M | $43.00M | $-141.00M | $-227.00M | $320.00M | $-169.00M | $-8.15B | $8.15B | $434.00M | $-41.00M | $9.00M | $89.00M | $61.00M |
| Cash at End of Period | $1.07B | $1.06B | $1.01B | $1.16B | $1.38B | $1.06B | $1.23B | $9.39B | $1.23B | $797.00M | $838.00M | $829.00M | $740.00M |
| Cash at Beginning of Period | $1.06B | $1.01B | $1.16B | $1.38B | $1.06B | $1.23B | $9.39B | $1.23B | $797.00M | $838.00M | $829.00M | $740.00M | $679.00M |
| Operating Cash Flow | $793.00M | $249.00M | $440.00M | $287.00M | $950.00M | $674.00M | $742.00M | $802.00M | $644.00M | $736.00M | $807.00M | $338.00M | $1.01B |
| Capital Expenditure | $-132.00M | $-59.00M | $-90.00M | $-153.00M | $-223.00M | $-114.00M | $-77.00M | $-55.00M | $-159.00M | $-103.00M | $-76.00M | $-37.00M | $-123.00M |
| Free Cash Flow | $661.00M | $190.00M | $350.00M | $134.00M | $727.00M | $560.00M | $665.00M | $747.00M | $485.00M | $633.00M | $731.00M | $301.00M | $886.00M |
Kenvue Dividends
Explore Kenvue's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
3.83%
Dividend Payout Ratio
150.68%
Dividend Paid & Capex Coverage Ratio
0.89x
Kenvue Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.205 | $0.205 | February 12, 2025 | February 12, 2025 | February 26, 2025 | January 16, 2025 |
| $0.205 | $0.205 | November 13, 2024 | November 13, 2024 | November 27, 2024 | October 17, 2024 |
| $0.205 | $0.205 | August 14, 2024 | August 14, 2024 | August 28, 2024 | July 25, 2024 |
| $0.2 | $0.2 | May 07, 2024 | May 08, 2024 | May 22, 2024 | April 25, 2024 |
| $0.2 | $0.2 | February 13, 2024 | February 14, 2024 | February 28, 2024 | January 25, 2024 |
| $0.2 | $0.2 | November 07, 2023 | December 08, 2023 | November 22, 2023 | October 26, 2023 |
| $0.2 | $0.2 | August 25, 2023 | August 28, 2023 | September 07, 2023 | July 20, 2023 |
Kenvue News
Read the latest news about Kenvue, including recent articles, headlines, and updates.
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high dividends. These are exactly the resilient defensive stocks in an un-loved healthcare sector that investors are now piling into as the VIX spikes.
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, with dividends from $1K invested meeting or exceeding their single share prices.
Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry.
3 Great Value Stocks That Could Crush the S&P 500 This Year
With the overall market looking expensive, it can be prudent for investors in search of new stocks to add to their portfolios to dig into companies that, for whatever reason, are trading at discounts. Some might have the potential to close their valuation gaps and become above-average investments.
Buy 3 "Safer" Dividend Kings Of 24 Out Of 52 For February
Seven of the top-ten Dividend Kings by yield offer annual dividends from a $1K investment exceeding their single share prices, making them attractive buys. Six Dividend Kings, including Altria Group and Hormel Foods, are currently fair-priced, with dividends meeting or exceeding their single-share prices. Analysts predict net gains between 15% and 45.53% for the top-ten Dividend Kings by February 2026, based on target prices.
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.
Buy 2 February S&P 500 Dividend Aristocrats Out Of 38 'Safer'
Five of the ten lowest-priced Dividend Aristocrats - Franklin Resources, Realty Income, Amcor, Hormel, and Kenvue - are recommended buys, offering dividends exceeding their single share prices. Analysts project net gains of 15.84% to 46.98% by February 2025 for the Top Ten Aristocrat Dogs, with an average gain of 21.63%. Ten Aristocrats show negative free cash flow margins, making them unsafe buys; Federal Realty, Kenvue, and PepsiCo are among them.
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. i.
Kenvue: An Intriguing Turnaround
Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.
Kenvue Is A Mediocre Candidate
Kenvue, the world's largest pure-play consumer health company, has a market cap of $37.96 billion but struggles with profitability despite decent growth. Management's cost-cutting initiatives show promise, but recent financials reveal mixed results, with revenue slightly up but net income and EBITDA declining. Kenvue's valuation appears relatively cheap compared to peers, yet its fundamentals don't justify a bullish outlook; thus, I rate it a 'hold'.
Kenvue, Inc. (KVUE) Q4 2024 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Thibaut Mongon - CEO Paul Ruh - CFO Sofya Tsinis - Head, IR Conference Call Participants Filippo Falorni - Citi Peter Grom - UBS Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Bonnie Herzog - Goldman Sachs Korinne Wolfmeyer - Piper Sandler Nik Modi - RBC Capital Markets Lauren Lieberman - Barclays Steve Powers - Deutsche Bank Operator Hello, and welcome to the Kenvue Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Kenvue (KVUE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Kenvue Reports Full Year and Fourth Quarter 2024 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. “We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we enter 2025 as a more competitive company with stronger foundations,” said Thibaut Mongon, Chief Executive Officer. “We remain focused on leveraging our increased brand investments to accelerate growth and deliver lon.
Neutrogena® Introduces Tate McRae as Global Brand Ambassador
On the Heels of its 10th Anniversary, the Brand's Iconic Hydro Boost Collection Is Revealing a Juicy, Fresh Take SKILLMAN, N.J. , Feb. 4, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) announces global sensation Tate McRae as the newest face of Neutrogena®.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KVUE.